BIOLUMA
A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in relapsed lung cancer and to evaluate biomarkers predictive for response to immune checkpoint inhibition
II
interventionell
National
Nivolumab (Opdivo®), Ipilimumab (Yervoy®)
Status: Rekrutierung beendet
Zeitraum
2017
2022
Patienten
90
90
25.10.2022
Klinische Settings
III, IV
2nd line
palliativ
Beteiligte
AIO-Arbeitsgruppen
Sponsor
Universität zu Köln
Förderer
Bristol-Myers Squibb (BMS)
Identifier
AIO-TRK-0116
AIO-TRK-0116
2016-003334-25
Kontakt
Leitung
Prof. Dr. med. Jürgen Wolf
Ansprechpartner*in
Prof. Dr. med. Jürgen Wolf
Telefon +49 221 47887008
E-Mail lungenkrebs@uk-koeln.de